Showing 5961-5970 of 6808 results for "".
- 8th Annual CSF Meeting Kicks Offhttps://practicaldermatology.com/news/8th-annual-csf-meeting-kicks-off/2458356/The Cosmetic Surgery Forum (CSF), now in its eighth year, was founded by NE-based dermatologist Joel Schlessinger, MD. CSF is a three-day multi-specialty educational symposium that covers the latest research, treatment and techniques in dermatology and cosmetic surgery. Unlike other meetings, res
- Study: Anxiety Linked to Skin Diseasehttps://practicaldermatology.com/news/study-anxiety-linked-to-skin-disease/2458359/Anxiety disorders tend to be followed by skin diseases, according to psychologists at the University of Basel in Switzerland and Ruhr University Bochum in Germany. The study, which appears in the journa
- ADAM Accepting Nominations for Practice Manager of the Yearhttps://practicaldermatology.com/news/adam-accepting-nominations-for-practice-manager-of-the-year/2458363/The Association of Dermatology Administrators and Managers is accepting nominations for its annual Practice Manager of the Year Award. Now in its fourth year, the Practice Manager of the Year Award recognizes the office professional who best demonstrates innovative thinking, ins
- Dermatology Scientist Sarah Millar Receives 2016 Focus Award For The Advancement Of Women In Medicinehttps://practicaldermatology.com/news/dermatology-scientist-sarah-millar-receives-2016-focus-award-for-the-advancement-of-women-in-medicine/2458364/Penn dermatology scientist Sarah E. Millar, PhD received the 2016 FOCUS Award for the Advancement of Women in Medicine. Millar, the Albert M. Kligman Endowed Professor and vice chair for basic science research in the department of Dermatology at the Perelman School of Medicine at the Univ
- Merz On The Move: Reflections On Fiscal Year 2015/16https://practicaldermatology.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2458365/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Consumer Reports IDs Teaching Hospitals That Expose Patients to Central Line Infectionshttps://practicaldermatology.com/news/consumer-reports-ids-teaching-hospitals-that-expose-patients-to-central-line-infections/2458366/Too many teaching hospitals are still exposing patients to dangerous bacteria via central line infections, according to Consumer Reports. The new report identifies
- New Day Cream, Gel Oil from Ceravehttps://practicaldermatology.com/news/new-day-cream-gel-oil-from-cerave/2458371/Cerave is expanding their Renewing product line. A new Cerave Skin Renewing Day Cream with Broad Spectrum SPF 30 sunscreen and Skin Renewing Gel Oil now join existing products in this line including Renewing Cream Serum and Renewing Night Cream.
- Mederma To Offer Products for Healthier Hair, Skin and Nailshttps://practicaldermatology.com/news/mederma-to-offer-products-for-healthier-hair-skin-and-nails/2458377/It’s not just scar and stretch mark reduction for Mederma anymore. Perhaps best known for such legacy products as scar gel and cream and stretch mark therapy, Mederma is now rolling out three new product lines for healthier hair, skin and nails.
- Precision Medicine in Action: Clinical Features May Help ID High Risk Melanoma Patientshttps://practicaldermatology.com/news/precision-medicine-in-action-clinical-featires-may-help-id-high-risk-melanoma-patients/2458379/Zeroing in on an individual’s risk factors for melanoma can help identify high-risk patients who may benefit from increased surveillance, new research suggests. Caroline G. Watts, M.P.H., of the University of Sydney, Australia, and coauthors examined clinical features associated wit
- FDA Approves Expanded Use Of Enbrel To Treat Children With Chronic Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-expanded-use-of-enbrel-to-treat-children-with-chronic-moderate-to-severe-plaque-psoriasis/2458383/The FDA has approved the supplemental Biologics License Application (sBLA) for the expanded use of Amgen's Enbrel (etanercept), making it the first and only systemic therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. The approval is based